Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab

References

• Burton DR, Weiss RA. AIDS/HIV. A boost for HIV vaccine design. Science 2010; 329:770 - 3; http://dx.doi.org/10.1126/science.1194693; PMID: 20705840
   PubMed Web of Science ®Google Scholar
• Donnelly JJ, Barnett SW, Dorenbaum A, Stamatatos L. Envelope-based HIV vaccines. Science 2002; 297:1277 - 8, author reply 1277-8; http://dx.doi.org/10.1126/science.297.5585.1277; PMID: 12194177
   PubMed Web of Science ®Google Scholar
• Mascola JR. Vaccines: engineering immune evasion. Nature 2006; 441:161; http://dx.doi.org/10.1038/441161a; PMID: 16688158
   PubMed Web of Science ®Google Scholar
• Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, Martin M, Overbaugh J, Watkins DI, Mahmoud A, et al. HIV vaccine research: the way forward. Science 2008; 321:530 - 2; http://dx.doi.org/10.1126/science.1161000; PMID: 18653883
   PubMed Web of Science ®Google Scholar
• Firer MA, Gellerman G. Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol 2012; 5:70; http://dx.doi.org/10.1186/1756-8722-5-70; PMID: 23140144
   PubMed Web of Science ®Google Scholar
• Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 2010; 14:529 - 37; http://dx.doi.org/10.1016/j.cbpa.2010.06.170; PMID: 20643572
   PubMed Web of Science ®Google Scholar
• Silverman DH, Delpassand ES, Torabi F, Goy A, McLaughlin P, Murray JL. Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues. Cancer Treat Rev 2004; 30:165 - 72; http://dx.doi.org/10.1016/j.ctrv.2003.07.006; PMID: 15023434
   PubMed Web of Science ®Google Scholar
• Silverman GJ. Anti-CD20 therapy and autoimmune disease: therapeutic opportunities and evolving insights. Front Biosci 2007; 12:2194 - 206; http://dx.doi.org/10.2741/2222; PMID: 17127456
   PubMed Web of Science ®Google Scholar
• Patel SP, Woodman SE. Profile of ipilimumab and its role in the treatment of metastatic melanoma. Drug Des Devel Ther 2011; 5:489 - 95; PMID: 22267918
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Ribas A. Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors. J Immunother 2010; 33:557 - 69; http://dx.doi.org/10.1097/CJI.0b013e3181dcd260; PMID: 20551840
   PubMed Web of Science ®Google Scholar
• Murillo O, Arina A, Hervas-Stubbs S, Gupta A, McCluskey B, Dubrot J, Palazón A, Azpilikueta A, Ochoa MC, Alfaro C, et al. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res 2008; 14:6895 - 906; http://dx.doi.org/10.1158/1078-0432.CCR-08-0285; PMID: 18980984
   PubMed Web of Science ®Google Scholar
• Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013; 13:5; PMID: 23390376
   PubMedGoogle Scholar
• McCormack PL, Keam SJ. Bevacizumab: a review of its use in metastatic colorectal cancer. Drugs 2008; 68:487 - 506; http://dx.doi.org/10.2165/00003495-200868040-00009; PMID: 18318567
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007; 357:39 - 51; http://dx.doi.org/10.1056/NEJMra043186; PMID: 17611206
   PubMed Web of Science ®Google Scholar
• Shadman KA, Wald ER. A review of palivizumab and emerging therapies for respiratory syncytial virus. Expert Opin Biol Ther 2011; 11:1455 - 67; http://dx.doi.org/10.1517/14712598.2011.608062; PMID: 21831008
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ, CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364:1897 - 908; http://dx.doi.org/10.1056/NEJMoa1102673; PMID: 21526923
   PubMed Web of Science ®Google Scholar
• Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10:301 - 16; http://dx.doi.org/10.1038/nri2761; PMID: 20414204
   PubMed Web of Science ®Google Scholar
• Isbister GK, Woods D, Alley S, O’Leary MA, Seldon M, Lincz LF. Endogenous thrombin potential as a novel method for the characterization of procoagulant snake venoms and the efficacy of antivenom. Toxicon 2010; 56:75 - 85; http://dx.doi.org/10.1016/j.toxicon.2010.03.013; PMID: 20338189
   PubMed Web of Science ®Google Scholar
• Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, Senter PD, Alley SC. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010; 16:888 - 97; http://dx.doi.org/10.1158/1078-0432.CCR-09-2069; PMID: 20086002
   PubMed Web of Science ®Google Scholar
• Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y, et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 2008; 3:e3942; http://dx.doi.org/10.1371/journal.pone.0003942; PMID: 19079604
   PubMed Web of Science ®Google Scholar
• van den Brand JM, Kreijtz JH, Bodewes R, Stittelaar KJ, van Amerongen G, Kuiken T, Simon J, Fouchier RA, Del Giudice G, Rappuoli R, et al. Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets. J Virol 2011; 85:2851 - 8; http://dx.doi.org/10.1128/JVI.01939-10; PMID: 21209108
   PubMed Web of Science ®Google Scholar
• Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E, Desrosiers RC, Clark KR. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 2009; 15:901 - 6; http://dx.doi.org/10.1038/nm.1967; PMID: 19448633
   PubMed Web of Science ®Google Scholar
• Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012; 481:81 - 4; http://dx.doi.org/10.1038/nature10660; PMID: 22139420
   PubMed Web of Science ®Google Scholar
• Limberis MP, Adam VS, Wong G, Gren J, Kobasa D, Ross TM, Kobinger GP, Tretiakova A, Wilson JM. Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza. Sci Transl Med 2013; 5:87ra72; http://dx.doi.org/10.1126/scitranslmed.3006299; PMID: 23720583
   PubMed Web of Science ®Google Scholar
• Shimada M, Abe S, Takahashi T, Shiozaki K, Okuda M, Mizukami H, Klinman DM, Ozawa K, Okuda K. Prophylaxis and treatment of Alzheimer’s disease by delivery of an adeno-associated virus encoding a monoclonal antibody targeting the amyloid Beta protein. PLoS One 2013; 8:e57606; http://dx.doi.org/10.1371/journal.pone.0057606; PMID: 23555563
   PubMed Web of Science ®Google Scholar
• Tjelle TE, Corthay A, Lunde E, Sandlie I, Michaelsen TE, Mathiesen I, Bogen B. Monoclonal antibodies produced by muscle after plasmid injection and electroporation. Mol Ther 2004; 9:328 - 36; http://dx.doi.org/10.1016/j.ymthe.2003.12.007; PMID: 15006599
   PubMed Web of Science ®Google Scholar
• Shedlock DJ, Silvestri G, Weiner DB. Monkeying around with HIV vaccines: using rhesus macaques to define ‘gatekeepers’ for clinical trials. Nat Rev Immunol 2009; 9:717 - 28; http://dx.doi.org/10.1038/nri2636; PMID: 19859066
   PubMed Web of Science ®Google Scholar
• Kutzler MA, Weiner DB. DNA vaccines: ready for prime time?. Nat Rev Genet 2008; 9:776 - 88; http://dx.doi.org/10.1038/nrg2432; PMID: 18781156
   PubMed Web of Science ®Google Scholar
• Mallilankaraman K, Shedlock DJ, Bao H, Kawalekar OU, Fagone P, Ramanathan AA, Ferraro B, Stabenow J, Vijayachari P, Sundaram SG, et al. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis 2011; 5:e928; http://dx.doi.org/10.1371/journal.pntd.0000928; PMID: 21264351
   PubMed Web of Science ®Google Scholar
• Yan J, Yoon H, Kumar S, Ramanathan MP, Corbitt N, Kutzler M, Dai A, Boyer JD, Weiner DB. Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine. Mol Ther 2007; 15:411 - 21; http://dx.doi.org/10.1038/sj.mt.6300036; PMID: 17235321
   PubMed Web of Science ®Google Scholar
• Morrow MP, Yan J, Pankhong P, Shedlock DJ, Lewis MG, Talbott K, Toporovski R, Khan AS, Sardesai NY, Weiner DB. IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques. Mol Ther 2010; 18:1714 - 23; http://dx.doi.org/10.1038/mt.2010.118; PMID: 20571540
   PubMed Web of Science ®Google Scholar
• Lang Kuhs KA, Ginsberg AA, Yan J, Wiseman RW, Khan AS, Sardesai NY, O’Connor DH, Weiner DB. Hepatitis C virus NS3/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses [corrected]. [corrected] Mol Ther 2012; 20:669 - 78; http://dx.doi.org/10.1038/mt.2011.188; PMID: 21952169
   PubMed Web of Science ®Google Scholar
• Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, Giffear M, Pankhong P, Khan AS, Broderick KE, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 2012; 4:ra138; http://dx.doi.org/10.1126/scitranslmed.3004414; PMID: 23052295
   PubMed Web of Science ®Google Scholar
• Hirao LA, Draghia-Akli R, Prigge JT, Yang M, Satishchandran A, Wu L, Hammarlund E, Khan AS, Babas T, Rhodes L, et al. Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis 2011; 203:95 - 102; http://dx.doi.org/10.1093/infdis/jiq017; PMID: 21148501
   PubMed Web of Science ®Google Scholar
• Laddy DJ, Yan J, Khan AS, Andersen H, Cohn A, Greenhouse J, Lewis M, Manischewitz J, King LR, Golding H, et al. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol 2009; 83:4624 - 30; http://dx.doi.org/10.1128/JVI.02335-08; PMID: 19211745
   PubMed Web of Science ®Google Scholar
• Hirao LA, Wu L, Satishchandran A, Khan AS, Draghia-Akli R, Finnefrock AC, Bett AJ, Betts MR, Casimiro DR, Sardesai NY, et al. Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques. Mol Ther 2010; 18:1568 - 76; http://dx.doi.org/10.1038/mt.2010.112; PMID: 20551910
   PubMed Web of Science ®Google Scholar
• Fagone P, Shedlock DJ, Bao H, Kawalekar OU, Yan J, Gupta D, Morrow MP, Patel A, Kobinger GP, Muthumani K, et al. Molecular adjuvant HMGB1 enhances anti-influenza immunity during DNA vaccination. Gene Ther 2011; 18:1070 - 7; http://dx.doi.org/10.1038/gt.2011.59; PMID: 21544096
   PubMed Web of Science ®Google Scholar
• Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, Kwon YD, Scheid JF, Shi W, Xu L, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010; 329:811 - 7; http://dx.doi.org/10.1126/science.1192819; PMID: 20616231
   PubMed Web of Science ®Google Scholar
• Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329:856 - 61; http://dx.doi.org/10.1126/science.1187659; PMID: 20616233
   PubMed Web of Science ®Google Scholar
• Li Y, O’Dell S, Walker LM, Wu X, Guenaga J, Feng Y, Schmidt SD, McKee K, Louder MK, Ledgerwood JE, et al. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol 2011; 85:8954 - 67; http://dx.doi.org/10.1128/JVI.00754-11; PMID: 21715490
   PubMed Web of Science ®Google Scholar
• Li Y, O’Dell S, Wilson R, Wu X, Schmidt SD, Hogerkorp CM, Louder MK, Longo NS, Poulsen C, Guenaga J, et al. HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins. J Virol 2012; 86:11231 - 41; http://dx.doi.org/10.1128/JVI.01543-12; PMID: 22875963
   PubMed Web of Science ®Google Scholar
• Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, Chung S, Strouse R, Mire-Sluis A, Schenerman M. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 2011; 10:101 - 11; http://dx.doi.org/10.1038/nrd3365; PMID: 21283105
   PubMed Web of Science ®Google Scholar
• Komoto M, Nakata B, Amano R, Yamada N, Yashiro M, Ohira M, Wakasa K, Hirakawa K. HER2 overexpression correlates with survival after curative resection of pancreatic cancer. Cancer Sci 2009; 100:1243 - 7; http://dx.doi.org/10.1111/j.1349-7006.2009.01176.x; PMID: 19432892
   PubMed Web of Science ®Google Scholar
• Aldrich JF, Lowe DB, Shearer MH, Winn RE, Jumper CA, Kennedy RC. Vaccines and immunotherapeutics for the treatment of malignant disease. Clin Dev Immunol 2010; 2010:697158; http://dx.doi.org/10.1155/2010/697158; PMID: 20936120
   PubMed Web of Science ®Google Scholar
• Xu M, Li J, Gulfo JV, Von Hofe E, Humphreys RE. MHC class II allosteric site drugs: new immunotherapeutics for malignant, infectious and autoimmune diseases. Scand J Immunol 2001; 54:39 - 44; http://dx.doi.org/10.1046/j.1365-3083.2001.00964.x; PMID: 11439146
   PubMed Web of Science ®Google Scholar
• Kutzler MA, Robinson TM, Chattergoon MA, Choo DK, Choo AY, Choe PY, Ramanathan MP, Parkinson R, Kudchodkar S, Tamura Y, et al. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol 2005; 175:112 - 23; PMID: 15972637
   PubMed Web of Science ®Google Scholar
• Aasa-Chapman MM, Hayman A, Newton P, Cornforth D, Williams I, Borrow P, Balfe P, McKnight A. Development of the antibody response in acute HIV-1 infection. AIDS 2004; 18:371 - 81; http://dx.doi.org/10.1097/00002030-200402200-00002; PMID: 15090788
   PubMed Web of Science ®Google Scholar
• Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, Li H, Leseka N, Treurnicht F, Mlisana K, Shaw GM, et al, CAPRISA 002 Study Team. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 2007; 81:6187 - 96; http://dx.doi.org/10.1128/JVI.00239-07; PMID: 17409164
   PubMed Web of Science ®Google Scholar
• Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003; 100:4144 - 9; http://dx.doi.org/10.1073/pnas.0630530100; PMID: 12644702
   PubMed Web of Science ®Google Scholar
• Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422:307 - 12; http://dx.doi.org/10.1038/nature01470; PMID: 12646921
   PubMed Web of Science ®Google Scholar
• Kamionka M. Engineering of therapeutic proteins production in Escherichia coli. Curr Pharm Biotechnol 2011; 12:268 - 74; http://dx.doi.org/10.2174/138920111794295693; PMID: 21050165
   PubMed Web of Science ®Google Scholar
• Muthumani K, Choo AY, Shedlock DJ, Laddy DJ, Sundaram SG, Hirao L, Wu L, Thieu KP, Chung CW, Lankaraman KM, et al. Human immunodeficiency virus type 1 Nef induces programmed death 1 expression through a p38 mitogen-activated protein kinase-dependent mechanism. J Virol 2008; 82:11536 - 44; http://dx.doi.org/10.1128/JVI.00485-08; PMID: 18799583
   PubMed Web of Science ®Google Scholar
• Muthumani K, Choo AY, Hwang DS, Premkumar A, Dayes NS, Harris C, Green DR, Wadsworth SA, Siekierka JJ, Weiner DB. HIV-1 Nef-induced FasL induction and bystander killing requires p38 MAPK activation. Blood 2005; 106:2059 - 68; http://dx.doi.org/10.1182/blood-2005-03-0932; PMID: 15928037
   PubMed Web of Science ®Google Scholar
• Muthumani K, Bagarazzi M, Conway D, Hwang DS, Manson K, Ciccarelli R, Israel Z, Montefiori DC, Ugen K, Miller N, et al. A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIV(mac)251 challenge in rhesus Macaques. Vaccine 2003; 21:629 - 37; http://dx.doi.org/10.1016/S0264-410X(02)00571-6; PMID: 12531331
   PubMed Web of Science ®Google Scholar
• Muthumani K, Shedlock DJ, Choo DK, Fagone P, Kawalekar OU, Goodman J, Bian CB, Ramanathan AA, Atman P, Tebas P, et al. HIV-mediated phosphatidylinositol 3-kinase/serine-threonine kinase activation in APCs leads to programmed death-1 ligand upregulation and suppression of HIV-specific CD8 T cells. J Immunol 2011; 187:2932 - 43; http://dx.doi.org/10.4049/jimmunol.1100594; PMID: 21856939
   PubMed Web of Science ®Google Scholar